Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin

Authors

  • Dr. Ah-Ng Tony Kong PhD,

    Corresponding author
    1. Division of Clinical Pharmacology, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
    2. College of Pharmacy, University of Illinois at Chicago
    Search for more papers by this author
  • Dr. Lisa Tomasko MS,

    1. Deparment of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey
    Search for more papers by this author
  • Dr. Scott A. Waldman MD, PhD,

    1. Division of Clinical Pharmacology, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Dr. Barbara Osborne RN, MPH,

    1. Division of Clinical Pharmacology, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Dr. Paul J. Deutsch MD, PhD,

    1. Deparment of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey
    Search for more papers by this author
  • Dr. Michael R. Goldberg MD, PhD,

    1. Deparment of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey
    Search for more papers by this author
  • Dr. Thorir D. Bjornsson MD, PhD

    1. Division of Clinical Pharmacology, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
    Search for more papers by this author

Department of Pharmaceutics and Pharmacodynamics (M/C 865), College of Pharmacy, The University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612–7230.

Abstract

Losartan, an orally active, nonpeptide angiotensin II receptor antagonist is being developed as a therapeutic agent for the treatment of hypertension and heart failure. Many patients requiring anticoagulant therapy with warfarin also may have hypertension or heart failure, and thus, are potential candidates for losartan therapy. This study was designed to investigate whether losartan at likely dosage levels would alter the anticoagulant response to warfarin. In a two-period, placebo-controlled, randomized, crossover study, ten healthy male subjects received a single oral dose of 30 mg warfarin sodium on the seventh day of a 13-day treatment with losartan, 100 mg daily by mouth, or placebo. Multiple plasma samples were collected over a 6-day period after both warfarin doses for the measurements of R- and S-warfarin concentrations and prothrombin times. The pharmacokinetics of R- and S-warfarin were comparable in the absence and presence of losartan (no significant effects of losartan on area under the curve, Cmax, or tmax). Losartan also had no significant effect on the anticoagulant effect of warfarin, as assessed by the area under the prothrombin time versus time curve and the maximum response for prothrombin time. The lack of pharmacokinetic or pharmacodynamic interaction between warfarin and losartan observed in this investigation suggests that a clinically important interaction between these drugs is unlikely to occur in patients requiring concomitant administration of both drugs.

Ancillary